Is Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) the right investment to pursue these days? Hedge funds are turning bullish. The number of long hedge fund bets rose by 3 recently.
According to most stock holders, hedge funds are perceived as slow, old financial tools of the past. While there are more than 8000 funds with their doors open at the moment, we choose to focus on the masters of this club, close to 450 funds. It is estimated that this group controls the lion’s share of the smart money’s total asset base, and by keeping an eye on their best stock picks, we have brought to light a few investment strategies that have historically outstripped the broader indices. Our small-cap hedge fund strategy beat the S&P 500 index by 18 percentage points per annum for a decade in our back tests, and since we’ve began to sharing our picks with our subscribers at the end of August 2012, we have topped the S&P 500 index by 23.3 percentage points in 8 months (check out a sample of our picks).
Just as beneficial, positive insider trading sentiment is another way to parse down the world of equities. As the old adage goes: there are many reasons for an upper level exec to sell shares of his or her company, but only one, very clear reason why they would initiate a purchase. Several empirical studies have demonstrated the valuable potential of this tactic if you know where to look (learn more here).
With these “truths” under our belt, it’s important to take a gander at the latest action regarding Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
How have hedgies been trading Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)?
In preparation for this quarter, a total of 7 of the hedge funds we track were bullish in this stock, a change of 75% from the first quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were upping their holdings considerably.
Of the funds we track, Nantahala Capital Management, managed by Wilmot B. Harkey and Daniel Mack, holds the most valuable position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Nantahala Capital Management has a $4.7 million position in the stock, comprising 0.8% of its 13F portfolio. The second largest stake is held by Jim Simons of Renaissance Technologies, with a $1.4 million position; less than 0.1%% of its 13F portfolio is allocated to the company. Other peers with similar optimism include Israel Englander’s Millennium Management, D. E. Shaw’s D E Shaw and John Overdeck and David Siegel’s Two Sigma Advisors.
As industrywide interest jumped, some big names have jumped into Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) headfirst. Millennium Management, managed by Israel Englander, assembled the biggest position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Millennium Management had 0.8 million invested in the company at the end of the quarter. John Overdeck and David Siegel’s Two Sigma Advisors also made a $0.2 million investment in the stock during the quarter. The other funds with new positions in the stock are Steven Cohen’s SAC Capital Advisors and Neil Chriss’s Hutchin Hill Capital.
What have insiders been doing with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)?
Insider buying is particularly usable when the company in focus has experienced transactions within the past 180 days. Over the last half-year time frame, Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has experienced zero unique insiders purchasing, and 4 insider sales (see the details of insider trades here).
Let’s also examine hedge fund and insider activity in other stocks similar to Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). These stocks are Pernix Therapeutics Holdings Inc (NASDAQ:PTX), DUSA Pharmaceuticals Inc (NASDAQ:DUSA), Depomed Inc (NASDAQ:DEPO), SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), and Lannett Company, Inc. (NYSEAMEX:LCI). All of these stocks are in the drug manufacturers – other industry and their market caps match SCMP’s market cap.